Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement

By Emilie Ruscoe · December 16, 2024, 10:08 PM EST

Investors in biotech company Ginkgo Bioworks Holdings Inc. have gotten final approval for their $17.75 million deal to end proposed class action claims that the company and its leaders distorted Ginkgo's...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Stuart v. Ginkgo Bioworks Holdings, Inc. et al

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

November 18, 2021

Recent Articles By Emilie

December 13, 2024
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
December 06, 2024
Two Firms To Rep CVS Investors In Benefit Unit Losses Suit
November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim
September 24, 2024
Biotech RenovaCare Investors Seek OK Of $2M Deal
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
August 02, 2024
Health Tech Co. Beats Investor Data Platform Fraud Claim